Category: Clinical Trial Update Region: Asia · China Company: Hutchmed Inc

HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China

By, Admin 1 min read
Share
HUTCHMED Initiates Phase I Study of BTK Inhibitor HMPL-760 in Patients with Previously Treated B-Cell Non-Hodgkin Lymphoma in China
HMPL-760 is the eleventh innovative potential oncology drug candidate discovered in-house by HUTCHMED HMPL-760 is HUTCHMED

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!